Ipatasertib

Generic Name: Ipatasertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₂ClN_₅O_₂

CAS Number: 1001264-89-6

Unique Ingredient Identifier: 524Y3IB4HQ

Background: Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Ipatasertib
Drug: Itraconazole

First Posted Date: 2017-07-19

Last Posted Date: 2017-11-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 15

Registration Number: NCT03222310

Locations: 🇺🇸
Covance Research Unit - Dallas, Dallas, Texas, United States

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

Phase 3

Completed

Conditions: Metastatic Prostate Cancer

Interventions: Drug: Abiraterone
Drug: Ipatasertib
Drug: Placebo
Drug: Prednisone/Prednisolone

First Posted Date: 2017-03-07

Last Posted Date: 2024-06-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1101

Registration Number: NCT03072238

Locations: 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 181 locations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Breast Carcinoma
Cervical Carcinoma
Liver Carcinoma
Malignant Uterine Neoplasm
Recurrent Gastric Carcinoma
Recurrent Head and Neck Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Prostate Carcinoma
Recurrent Rectal Carcinoma

Interventions: Drug: Afatinib
Drug: Capivasertib
Drug: Binimetinib
Drug: Adavosertib
Procedure: Biospecimen Collection
Other: Cytology Specimen Collection Procedure
Drug: Afatinib Dimaleate
Drug: Dabrafenib
Drug: Defactinib
Drug: Fexagratinib
Drug: Dasatinib
Drug: Ipatasertib
Procedure: Biopsy
Drug: Crizotinib
Drug: Dabrafenib Mesylate
Drug: Taselisib
Drug: Sapanisertib
Drug: PI3K-beta Inhibitor GSK2636771
Drug: Defactinib Hydrochloride
Drug: Palbociclib
Biological: Nivolumab
Drug: Copanlisib
Drug: Ulixertinib
Biological: Trastuzumab Emtansine
Drug: Copanlisib Hydrochloride
Biological: Relatlimab
Procedure: Computed Tomography
Drug: Trametinib
Biological: Pertuzumab
Drug: Erdafitinib
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Drug: Larotrectinib
Procedure: Echocardiography
Drug: Osimertinib
Biological: Trastuzumab
Drug: Larotrectinib Sulfate
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Vismodegib
Drug: Sunitinib Malate
Procedure: Radionuclide Imaging

First Posted Date: 2015-06-08

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6452

Registration Number: NCT02465060

Locations: 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States

and more 1416 locations

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ipatasertib
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2014-11-26

Last Posted Date: 2018-10-17

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 151

Registration Number: NCT02301988

Locations: 🇪🇸
Hospital Universitario Virgen Macarena, Seville, Sevilla, Spain
🇺🇸
Arizona Oncology Associates, PC-CASA, Tucson, Arizona, United States
🇺🇸
Rocky Mountain Cancer Center - Lakewood (West), Lakewood, Colorado, United States

and more 39 locations

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Ipatasertib
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2014-06-13

Last Posted Date: 2021-03-10

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 124

Registration Number: NCT02162719

Locations: 🇺🇸
West Virginia University Hospitals Inc, Morgantown, West Virginia, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 40 locations

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Ipatasertib
Drug: Leucovorin
Drug: Placebo
Drug: Oxaliplatin

First Posted Date: 2013-07-11

Last Posted Date: 2022-03-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 153

Registration Number: NCT01896531

Locations: 🇺🇸
Univ of Calif, Los Angeles; Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital;Oncology, Boston, Massachusetts, United States
🇮🇹
Azienda Ospedaliero Universitaria Pisana; Uff. Sperim. Clin. U.O. Farmaceutica, Pisa, Toscana, Italy

and more 31 locations

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Ipatasertib
Drug: Cobimetinib

First Posted Date: 2012-03-23

Last Posted Date: 2016-03-28

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 67

Registration Number: NCT01562275

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone
Drug: Placebo
Drug: Ipatasertib
Drug: Apitolisib
Drug: Prednisone
Drug: Prednisolone

First Posted Date: 2011-12-06

Last Posted Date: 2023-09-14

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 298

Registration Number: NCT01485861

Locations: 🇺🇸
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
🇺🇸
Kaiser Permanente Medical Ctr, Honolulu, Hawaii, United States
🇨🇿
Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia

and more 56 locations

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Enzalutamide
Drug: Docetaxel
Drug: 5-FU
Drug: Ipatasertib
Drug: Paclitaxel
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2011-05-30

Last Posted Date: 2022-01-12

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 122

Registration Number: NCT01362374

Locations: 🇫🇷
Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France
🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy